中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2010年
28期
1986-1988
,共3页
食管肿瘤%紫杉酚%持续静脉滴注%奥沙利铂
食管腫瘤%紫杉酚%持續靜脈滴註%奧沙利鉑
식관종류%자삼분%지속정맥적주%오사리박
Esophageal neoplasms%Paclitaxel%Continuous infusion%Oxaliplatin
目的 观察分析紫杉醇24 h持续静脉滴注联合奥沙利铂(L-OHP)治疗晚期食管癌的近期疗效和安全性.方法 43例TNM分期为Ⅲ～Ⅳ期晚期食管痛患者中,鳞癌32例,腺癌11例,36例为初治患者,7例曾接受过化疗,其中4例接受过紫杉类治疗,中位年龄56岁.紫杉醇175 ms/m2,24 h持续静脉滴注,第2天L-OHP 130 ms/m2静脉滴注,21 d为1个周期.结果 43例患者共完成130个化疗周期,可评价疗效及毒副反应41例,完全缓解(CR)4例,部分缓解(PR)16例,疾病稳定(SD)9例,疾病进展(PD)12例,有效率(RR)48.7%.其中鳞癌可评价者30例,CR4例,PR 14例,sD 4例,PD 8例,RR 60.0%,腺癌可评价者11例,CR 0例,PR 2例,SD 5例,PD 4例,RR 18.2%,经统计分析鳞癌有效率显著高于腺癌组(P<0.05),该方案主要的不良反应为中性粒细胞减少,Ⅲ～Ⅳ度41.4%,脱发、周围神经毒性、肌肉关节痛等,多以Ⅰ～Ⅱ度为主,发生率分别为60.9%,22%,19.5%.结论 紫杉醇24 h持续静脉滴注联合L-OHP治疗晚期食管癌近期疗效肯定,毒副反应耐受性好,可以考虑作为晚期食管癌的治疗方案.
目的 觀察分析紫杉醇24 h持續靜脈滴註聯閤奧沙利鉑(L-OHP)治療晚期食管癌的近期療效和安全性.方法 43例TNM分期為Ⅲ～Ⅳ期晚期食管痛患者中,鱗癌32例,腺癌11例,36例為初治患者,7例曾接受過化療,其中4例接受過紫杉類治療,中位年齡56歲.紫杉醇175 ms/m2,24 h持續靜脈滴註,第2天L-OHP 130 ms/m2靜脈滴註,21 d為1箇週期.結果 43例患者共完成130箇化療週期,可評價療效及毒副反應41例,完全緩解(CR)4例,部分緩解(PR)16例,疾病穩定(SD)9例,疾病進展(PD)12例,有效率(RR)48.7%.其中鱗癌可評價者30例,CR4例,PR 14例,sD 4例,PD 8例,RR 60.0%,腺癌可評價者11例,CR 0例,PR 2例,SD 5例,PD 4例,RR 18.2%,經統計分析鱗癌有效率顯著高于腺癌組(P<0.05),該方案主要的不良反應為中性粒細胞減少,Ⅲ～Ⅳ度41.4%,脫髮、週圍神經毒性、肌肉關節痛等,多以Ⅰ～Ⅱ度為主,髮生率分彆為60.9%,22%,19.5%.結論 紫杉醇24 h持續靜脈滴註聯閤L-OHP治療晚期食管癌近期療效肯定,毒副反應耐受性好,可以攷慮作為晚期食管癌的治療方案.
목적 관찰분석자삼순24 h지속정맥적주연합오사리박(L-OHP)치료만기식관암적근기료효화안전성.방법 43례TNM분기위Ⅲ～Ⅳ기만기식관통환자중,린암32례,선암11례,36례위초치환자,7례증접수과화료,기중4례접수과자삼류치료,중위년령56세.자삼순175 ms/m2,24 h지속정맥적주,제2천L-OHP 130 ms/m2정맥적주,21 d위1개주기.결과 43례환자공완성130개화료주기,가평개료효급독부반응41례,완전완해(CR)4례,부분완해(PR)16례,질병은정(SD)9례,질병진전(PD)12례,유효솔(RR)48.7%.기중린암가평개자30례,CR4례,PR 14례,sD 4례,PD 8례,RR 60.0%,선암가평개자11례,CR 0례,PR 2례,SD 5례,PD 4례,RR 18.2%,경통계분석린암유효솔현저고우선암조(P<0.05),해방안주요적불량반응위중성립세포감소,Ⅲ～Ⅳ도41.4%,탈발、주위신경독성、기육관절통등,다이Ⅰ～Ⅱ도위주,발생솔분별위60.9%,22%,19.5%.결론 자삼순24 h지속정맥적주연합L-OHP치료만기식관암근기료효긍정,독부반응내수성호,가이고필작위만기식관암적치료방안.
Objective To evaluate the efficacy and safety of a 24-hour continuous infusion of paclitaxel in combination with oxaliplatin in the treatment of advanced esophageal cancer.Methods A total of 43 subjects with Ⅲ -Ⅳ stage advanced esophageal cancer were enrolled from March 2008 to June 2009.There were squamous cell carcinoma (n=32) and adenocarcinoma (n = 11 ).Among them, 36 patients had no prior chemotherapy, 7 patients received adjuvant chemotherapy and 4 accepted taxane-based regiments.The median age was 56 years old.All patients were treated with paclitaxel 175 mg/m2 by a 24-hour continuous infusion, oxaliplatin 130 mg/m2 at Day 2, 3 weeks as one cycle.Results Forty-three patients completed 130 cycles ( median: 3 ) .And the efficacy and safety of 41 patients could be evaluated.According to the WHO standard, there were complete response (CR) (n=4), partial response (PR) (n=16), stable disease (SD) (n=9), progressive disease (PD) (n=12) and response rate (RR) 48.7%.Thirty eases of squamous cell carcinoma could be evaluated, CR 4, PR 14, SD 4, PD 8, RR 60.0%;Adenoearcinoma CR 0, PR 2, SD 5, PD 4, RR 18.2%.Statistical test show that RR of squamous was higher than that of adenoearcinoma (P < 0.05).The most common toxicity was hematological.Grade Ⅲ -Ⅳ neutropenia was seen in 16 patients (41.4%), alopocia 60.9%, vomiting 26.8%, neuropathy 22% and myalgia 19.5%.Most of them were of Grade Ⅰ - Ⅱ.Conclusions The efficacy of a 24-hour continuous infusion of paclitaxel plus oxaliplatin in the treatment of advanced esophageal cancer is excellent.All toxicities are well tolerated.So this protocol may be considered a main regimen in the treatment of advanced esophageal cancer.
